RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Jodie Fleming to Xenograft Model Antitumor Assays

Back to Details
This is a "connection" page, showing publications Jodie Fleming has written about Xenograft Model Antitumor Assays.
Jodie Fleming
Connection Strength
0.035
Xenograft Model Antitumor Assays
  1. Oladapo HO, Tarpley M, Sauer SJ, Addo KA, Ingram SM, Strepay D, Ehe BK, Chdid L, Trinkler M, Roques JR, Darr DB, Fleming JM, Devi GR, Williams KP. Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in?vivo tumor growth of inflammatory breast cancer cells. Cancer Lett. 2017 12 28; 411:136-149.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support